CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $329,000 | -21.5% | 2,942 | +13.8% | 0.00% | -20.0% |
| Q2 2021 | $419,000 | +33.0% | 2,586 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $315,000 | -9.7% | 2,586 | -67.2% | 0.00% | -33.3% |
| Q3 2018 | $349,000 | -61.0% | 7,876 | -48.4% | 0.01% | -66.7% |
| Q2 2018 | $896,000 | +28.6% | 15,251 | -0.0% | 0.02% | +28.6% |
| Q1 2018 | $697,000 | +88.4% | 15,252 | -3.2% | 0.01% | +75.0% |
| Q4 2017 | $370,000 | – | 15,752 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |